CRVS
Corvus Pharmaceuticals, Inc. · Healthcare
Insiders bought $83K of Corvus Pharmaceuticals, Inc. in the last 12 months
1 insider bought on 1 day.
CRVS over the last year
Largest buyers, last 12 months
CRVS after insider buys
3 months after each buy, from the first price a copier could get.
6 buys since 2016 with 3 months of prices.
Every filing
42 insider filings since 2016, newest first
Richard A Md Miller · President and CEO
William Benton Jones · Insider
Richard A Md Miller · President and CEO
Leiv Lea · CFO
Richard A Md Miller · President and CEO
Leiv Lea · CFO
Richard A Md Miller · President and CEO
Ecor1 Capital, LLC · 10% owner
Orbimed Advisors LLC · Director and 10% owner
Peter A. Thompson · Director and 10% owner
Richard A Md Miller · President and CEO
Peter A. Thompson · Director and 10% owner
Orbimed Advisors LLC · Director and 10% owner
Richard A Md Miller · President and CEO
Novo Holdings A/s · 10% owner
Richard A Md Miller · President and CEO
Peter A. Thompson · Director and 10% owner
Orbimed Advisors LLC · Director and 10% owner
Richard A Md Miller · President and CEO
Novo Holdings A/s · 10% owner
Peter A. Thompson · Director and 10% owner
Orbimed Advisors LLC · Director and 10% owner
Richard A Md Miller · President and CEO
Richard A Md Miller · President and CEO
Leiv Lea · CFO
Leiv Lea · CFO
Richard A Md Miller · President and CEO
Richard A Md Miller · President and CEO
Peter A. Thompson · Director and 10% owner
Orbimed Advisors LLC · Director and 10% owner
Novo Holdings A/s · 10% owner
Terry P Gould · Director and 10% owner
Adams Street Partners LLC · 10% owner
Richard A Md Miller · President and CEO
Richard A Md Miller · President and CEO
Richard A Md Miller · President and CEO
Peter A. Thompson · Director and 10% owner
Orbimed Advisors LLC · Director and 10% owner
Peter A. Thompson · Director and 10% owner
Orbimed Advisors LLC · Director and 10% owner
Richard A Md Miller · President and CEO
A/s Novo · 10% owner
About Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.